{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fned-talk-btki-overview-tDiDD2RH","width":444,"version":"1.0","type":"rich","title":"BTK Inhibitors in CLL and Lymphomas: Overview and  Current Indications","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/e7b68d10-53a3-41c1-ac47-9d7123171414/btki-ae-and-adherence-wc-podcasticon-overview.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/5bb10e48-8c5c-47cf-966e-1677b8c55b81\" height=\"200\" width=\"100%\" title=\"BTK Inhibitors in CLL and Lymphomas: Overview and  Current Indications\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Beth Faiman, PhD, MSN, APRN-BC, AOCN, provide a nursing-focused overview of BTK inhibitors in the treatment of CLL and other B-cell malignancies including the most recent evidence reported from major oncology conferences."}